<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693392</url>
  </required_header>
  <id_info>
    <org_study_id>T/EM-F/Pharma/14/05</org_study_id>
    <nct_id>NCT02693392</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes</brief_title>
  <official_title>Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes: An Add-On Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chemical Resources</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study, hydroalcoholic Fenugreek seed extract will used add-on to the existing
      therapy in patients with type-2 diabetes. The efficacy and safety of the extract will be
      evaluated using standard methodology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trigonella foenum-graecum, commonly known as Fenugreek, is a plant that has been extensively
      used as a source of antidiabetic compounds, from its seeds, leaves and extracts in different
      systems of medicine in asia. Fenugreek is traditionally used in India, especially in the
      Ayurvedic and Unani systems. Preliminary animal and human studies suggest possible
      hypoglycemic and anti-hyperlipidemic properties of fenugreek seed powder taken orally. In a
      randomized placebo controlled study conducted by Gupta et al showed that two month treatment
      with the hydro-alcoholic extract of fenugreek seeds improved glycemic control in 12
      non-insulin dependent diabetes mellitus patients. In addition, there was improvement in
      insulin sensitivity and plasma lipid profile. Fenugreek extract was also well tolerated in
      diabetic patients.

      In the proposed study, hydroalcoholic Fenugreek seed extract will used add-on to the existing
      therapy in patients with type-2 diabetes. The efficacy and safety of the extract will be
      evaluated using standard methodology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>Change from baseline HbA1c over 12 weeks</time_frame>
    <description>HbA1c will be evaluated using Hb variant (HPLC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>Change from baseline Fasting Blood Glucose over 12 weeks</time_frame>
    <description>METHOD : SPECTROPHOTOMETRY HEXOKINASE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin</measure>
    <time_frame>Change from baseline Serum Insulin over 12 weeks</time_frame>
    <description>by CHEMILUMINESCENCE method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-Peptide</measure>
    <time_frame>Change from baseline Serum C-Peptide over 12 weeks</time_frame>
    <description>by CHEMILUMINESCENCE method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Test</measure>
    <time_frame>Change from baseline Renal function test over 12 weeks</time_frame>
    <description>by Spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function Test</measure>
    <time_frame>Change from baseline Liver function test over 12 weeks</time_frame>
    <description>by Spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology (whole blood cell count)</measure>
    <time_frame>Change from baseline Hematology over 12 weeks</time_frame>
    <description>Automated particle cell counter and microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary sugar</measure>
    <time_frame>Change from baseline Urinary over 12 weeks</time_frame>
    <description>Semi-quantitative Biochemical test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-prandial Blood Glucose</measure>
    <time_frame>Change from baseline post-prandial Blood Glucose over 12 weeks</time_frame>
    <description>METHOD: SPECTROPHOTOMETRY HEXOKINASE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type-2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up without add-on fenugreek extract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenugreek</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up with add-on fenugreek extract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]</intervention_name>
    <description>Patients receiving either of the following oral hypoglycemic agents
Sulfonylurea based oral hypoglycemic agents
Metformin based oral hypoglycemic agents
Metformin plus Sulfonylurea based oral hypoglycemic agents</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Fenugreek</arm_group_label>
    <other_name>Metformin, Sulfonylurea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fenugreek Seed extract</intervention_name>
    <description>Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy</description>
    <arm_group_label>Fenugreek</arm_group_label>
    <other_name>Capsule Fenfuro 500 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from Type-2 Diabetes of less than 10 years duration

          -  Patients with HbA1c &gt;7.0%

          -  Patients with fasting plasma glucose not exceeding 180 mg/dL

          -  Patients with Negative Urine sugar

          -  Patients who are on oral hypoglycaemic agents containing either Metformin or
             Sulfonylurea or both

          -  There should not be any change their in anti-diabetic treatment for at least one month

        Exclusion Criteria:

          -  Patients with diabetes other than type-2 diabetes mellitus

          -  Patients with evidence of renal disease (S. Creatinine &gt; 1.5mg/dL)

          -  Patients with evidence of liver disease (AST/ALT &gt;3 times of normal

          -  Pregnant and lactating mothers and women intending pregnancy

          -  Patients who participated in any other clinical trial within the last 30 days

          -  Patients with history of any hemoglobinopathy

          -  History of intolerance or hypersensitivity to Fenugreek
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Debasish Hota, MD, DM</last_name>
    <phone>+91-674-2476011</phone>
    <email>debhota@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medicine and Department of Pharmacology, AIIMS</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debasish Hota, MD, DM</last_name>
      <phone>+91-674-2476011</phone>
      <email>debhota@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rituparna Maiti, MD</last_name>
      <email>rituparnamaiti@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Biswa M Padhy, MD, DM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anupam Dey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Binod K Patro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India. 2001 Nov;49:1057-61.</citation>
    <PMID>11868855</PMID>
  </results_reference>
  <results_reference>
    <citation>Neelakantan N, Narayanan M, de Souza RJ, van Dam RM. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. Nutr J. 2014 Jan 18;13:7. doi: 10.1186/1475-2891-13-7.</citation>
    <PMID>24438170</PMID>
  </results_reference>
  <results_reference>
    <citation>Baquer NZ, Kumar P, Taha A, Kale RK, Cowsik SM, McLean P. Metabolic and molecular action of Trigonella foenum-graecum (fenugreek) and trace metals in experimental diabetic tissues. J Biosci. 2011 Jun;36(2):383-96. Review.</citation>
    <PMID>21654091</PMID>
  </results_reference>
  <results_reference>
    <citation>Hannan JM, Ali L, Rokeya B, Khaleque J, Akhter M, Flatt PR, Abdel-Wahab YH. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br J Nutr. 2007 Mar;97(3):514-21.</citation>
    <PMID>17313713</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>Dr Debasish Hota</investigator_full_name>
    <investigator_title>Professor &amp; Head</investigator_title>
  </responsible_party>
  <keyword>Fenugreek seed extract</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Blood glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenugreek seed meal</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

